〔Abstract〕 Objective To study the effects of different hepatoprotective drugs on the imbalance of pro-inflammatory factors and anti-inflammatory factors in patients with liver injury caused by anti-tuberculosis drugs. Methods A total of 168 pulmonary tuberculosis patients admitted to Honghu Specialized Hospital for Schistosomiasis from July 2018 to December 2019 were selected and divided into non-hepatoprotective group (52 cases) and bicyclol group (65 cases) and the silibinin group (51 cases) according to the random number table method. The non-hepatoprotective group received conventional anti-tuberculosis treatment, the bicyclol group was treated with bicyclol tablets on the basis of conventional anti-tuberculosis treatment, and the silibinin group was treated with silibinin capsules on the basis of conventional anti-tuberculosis treatment. Compare the results of each group treatment effect. Results The patients in the non-hepatoprotective group after treatment accounted for more liver injury severity ≥ grade 3 than the silibinin group and the bicyclol group, and the difference was statistically significant (P < 0.05). There was no significant difference in the proportion of patients in the silibinin group with liver injury severity ≥ grade 3 compared with the bicyclol group (P > 0.05); adverse effects in the liver-protective group, silibinin group, and bicyclol group The incidence of reaction was 11.53%, 11.76%, 10.77%, and the difference was not statistically significant (P > 0.05); Interleukin-17 (IL-17) in the silibinin group and bicyclol group after 4 weeks and 8 weeks of treatment , Interferon-γ (IFN-γ) were increased compared with before treatment, IL-10 was lower than before treatment, the difference was statistically significant (P < 0.05). There was no significant difference in IL-17, IFN-γ, and IL-10 in the non-hepatoprotective group after 4 weeks of treatment (P > 0.05). After 8 weeks of treatment, the IL-17 and IFN-γ of the patients in the non-hepatoprotective group were both higher than before treatment, and IL-10 was lower than before treatment.The difference was statistically significant (P < 0.05). In addition, the IL-17 and IFN-γ of patients in the bicyclol group were higher than those in the silibinin group, and the IL-10 was lower than that in the silibinin group after 4 weeks of treatment. The difference was statistically significant (P < 0.05). There was no statistically significant difference in IL-17, IFN-γ, and IL-10 of patients in the bicyclol group after 8 weeks of treatment (P > 0.05). Conclusion The therapeutic effect of bicyclol tablets is better than that of silibinin capsules in the early treatment, but the two hepatoprotective drugs can achieve better therapeutic effects, induce the secretion of pro-inflammatory factors, and down-regulate the expression of anti-inflammatory factors in the blood. However, the lack of circulation When verifying the medical evidence, hepatoprotective drugs should be used with caution.